Stock DNA
Pharmaceuticals & Biotechnology
CNY 13,783 Million (Large Cap)
26.00
NA
3.15%
-0.37
13.09%
3.41
Revenue and Profits:
Net Sales:
755 Million
(Quarterly Results - Jun 2025)
Net Profit:
284 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.57%
0%
-8.57%
6 Months
1.35%
0%
1.35%
1 Year
9.33%
0%
9.33%
2 Years
3.97%
0%
3.97%
3 Years
2.98%
0%
2.98%
4 Years
-8.27%
0%
-8.27%
5 Years
-8.47%
0%
-8.47%
Tibet Cheezheng Tibetan Medicine Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.25%
EBIT Growth (5y)
15.53%
EBIT to Interest (avg)
9.32
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
0.38
Tax Ratio
10.20%
Dividend Payout Ratio
34.61%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.58%
ROE (avg)
15.58%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
3.41
EV to EBIT
20.22
EV to EBITDA
16.31
EV to Capital Employed
4.85
EV to Sales
4.99
PEG Ratio
NA
Dividend Yield
3.15%
ROCE (Latest)
23.99%
ROE (Latest)
13.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
754.70
629.30
19.93%
Operating Profit (PBDIT) excl Other Income
300.70
241.80
24.36%
Interest
14.50
14.30
1.40%
Exceptional Items
24.70
25.00
-1.20%
Consolidate Net Profit
284.40
228.40
24.52%
Operating Profit Margin (Excl OI)
349.40%
329.80%
1.96%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 19.93% vs 20.05% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 24.52% vs 4.67% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,298.50
2,010.30
14.34%
Operating Profit (PBDIT) excl Other Income
675.50
562.10
20.17%
Interest
60.40
66.80
-9.58%
Exceptional Items
105.10
37.10
183.29%
Consolidate Net Profit
581.40
579.20
0.38%
Operating Profit Margin (Excl OI)
232.80%
231.90%
0.09%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 14.34% vs -0.24% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 0.38% vs 23.34% in Dec 2023
About Tibet Cheezheng Tibetan Medicine Co., Ltd. 
Tibet Cheezheng Tibetan Medicine Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






